Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CNTTF NASDAQ:FIXX NASDAQ:KNSA NYSE:MYOV NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTTFCannTrust$0.00$4.35▼$11.97$1.01B4.52528,025 shs1.43 million shsFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsKNSAKiniksa Pharmaceuticals International$28.10-2.9%$27.71$17.82▼$30.69$2.05B0.05555,288 shs164,916 shsMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shsSTOKStoke Therapeutics$11.90-1.2%$10.61$5.35▼$16.15$652.31M1.14672,671 shs212,308 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTTFCannTrust0.00%0.00%0.00%0.00%0.00%FIXXHomology Medicines0.00%0.00%0.00%0.00%0.00%KNSAKiniksa Pharmaceuticals International+0.52%+3.93%-2.75%+49.92%+38.12%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%STOKStoke Therapeutics+0.17%+4.83%+5.99%+71.51%-9.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTTFCannTrustN/AN/AN/AN/AN/AN/AN/AN/AFIXXHomology Medicines0.7922 of 5 stars0.00.00.04.80.60.80.6KNSAKiniksa Pharmaceuticals International3.6167 of 5 stars3.54.00.00.02.83.30.6MYOVMyovant SciencesN/AN/AN/AN/AN/AN/AN/AN/ASTOKStoke Therapeutics3.9195 of 5 stars3.70.00.04.81.60.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTTFCannTrust 0.00N/AN/AN/AFIXXHomology Medicines 0.00N/AN/AN/AKNSAKiniksa Pharmaceuticals International 3.00Buy$39.3338.99% UpsideMYOVMyovant Sciences 0.00N/AN/AN/ASTOKStoke Therapeutics 3.33Buy$24.75108.09% UpsideCurrent Analyst Ratings BreakdownLatest STOK, KNSA, MYOV, FIXX, and CNTTF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.007/1/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.005/14/2025STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $35.004/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/16/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTTFCannTrust$15.96M0.00N/AN/AN/ANaNFIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00KNSAKiniksa Pharmaceuticals International$423.24M4.88N/AN/A$6.60 per share4.29MYOVMyovant Sciences$230.97M11.36N/AN/A($5.04) per share-5.35STOKStoke Therapeutics$36.56M17.76N/AN/A$4.32 per share2.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTTFCannTrustN/A$0.07137.180.00N/AN/AN/AN/AN/AFIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/AKNSAKiniksa Pharmaceuticals International-$43.19M-$0.25N/A113.20N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)MYOVMyovant Sciences-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/ASTOKStoke Therapeutics-$88.98M$0.7915.01N/AN/A26.33%19.08%15.72%8/5/2025 (Estimated)Latest STOK, KNSA, MYOV, FIXX, and CNTTF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025STOKStoke Therapeutics-$0.0905N/AN/AN/A$31.51 millionN/A7/22/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.08N/AN/AN/AN/AN/A4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTTFCannTrustN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTTFCannTrustN/AN/AN/AFIXXHomology MedicinesN/A7.257.25KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43MYOVMyovant SciencesN/A1.571.45STOKStoke TherapeuticsN/A8.418.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTTFCannTrust0.08%FIXXHomology Medicines31.32%KNSAKiniksa Pharmaceuticals International53.95%MYOVMyovant Sciences30.62%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCNTTFCannTrustN/AFIXXHomology Medicines16.10%KNSAKiniksa Pharmaceuticals International53.48%MYOVMyovant Sciences1.90%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTTFCannTrustN/A105.61 millionN/ANot OptionableFIXXHomology Medicines758.13 million48.77 millionOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableMYOVMyovant Sciences40797.24 million95.39 millionNot OptionableSTOKStoke Therapeutics10054.60 million49.41 millionOptionableSTOK, KNSA, MYOV, FIXX, and CNTTF HeadlinesRecent News About These CompaniesLille rival Aston Villa in race for Stoke’s Sol SidibéJuly 10 at 10:48 AM | sports.yahoo.comAston Villa want Stoke City midfielder Sol SidibeJuly 10 at 10:48 AM | sports.yahoo.comStoke City vs Shrewsbury LIVE Score Updates: Match CanceledJuly 10 at 10:48 AM | vavel.comVCouncil still against Stoke-on-Trent 'merger' as devolution decision gets nearerJuly 10 at 10:48 AM | msn.comLive updates after 'accident' on Stoke-on-Trent roadJuly 10 at 10:48 AM | stokesentinel.co.ukSStoke City close in on fourth summer signingJuly 10 at 10:48 AM | msn.comBiogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 10 at 7:00 AM | globenewswire.comStoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 10 at 7:00 AM | businesswire.comLive updates as firefighters on scene of Stoke-on-Trent blazeJuly 8 at 6:12 PM | stokesentinel.co.ukSPolice helicopter tracks 4 masked kids on stolen motorbikes in Stoke-on-Trent parkJuly 8 at 6:12 PM | msn.comStoke-on-Trent firm collapses into administrationJuly 8 at 6:12 PM | msn.comDriver dies in Royal Stoke after hitting treeJuly 8 at 6:12 PM | msn.comStoke City move early for 'lethal' rising Manchester City star in second signing of the dayJuly 7, 2025 | msn.comNew Hanford waste incinerator could keep patients warm at Royal StokeJuly 7, 2025 | msn.comStoke sign Talovierov and Man City's MubamaJuly 7, 2025 | msn.comZebra crossings to be installed outside TWO schools on same Stoke-on-Trent roadJuly 5, 2025 | msn.comStoke-on-Trent-based Prohire Limited falls into administrationJuly 5, 2025 | bbc.co.ukDONE DEAL: Stoke snap up Man City striker MubamaJuly 5, 2025 | tribalfootball.comTMaksym Talovierov makes 'cold nights' promise with brilliant Stoke City statementJuly 5, 2025 | msn.comMubama set for Stoke loan switchJuly 5, 2025 | sports.yahoo.comStoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at Needham & Company LLCJuly 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTOK, KNSA, MYOV, FIXX, and CNTTF Company DescriptionsCannTrust OTCMKTS:CNTTFCannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.Homology Medicines NASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Kiniksa Pharmaceuticals International NASDAQ:KNSA$28.10 -0.85 (-2.92%) As of 02:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Myovant Sciences NYSE:MYOVMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.Stoke Therapeutics NASDAQ:STOK$11.90 -0.14 (-1.16%) As of 02:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
